GSA Capital Partners LLP Makes New Investment in BioAtla, Inc. (NASDAQ:BCAB)

GSA Capital Partners LLP bought a new position in shares of BioAtla, Inc. (NASDAQ:BCAB) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 353,769 shares of the company’s stock, valued at approximately $623,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BCAB. Vanguard Group Inc. increased its position in shares of BioAtla by 0.8% during the first quarter. Vanguard Group Inc. now owns 2,099,037 shares of the company’s stock valued at $7,221,000 after acquiring an additional 17,667 shares during the last quarter. Acadian Asset Management LLC raised its stake in shares of BioAtla by 57.6% during the 1st quarter. Acadian Asset Management LLC now owns 155,188 shares of the company’s stock worth $532,000 after purchasing an additional 56,748 shares during the period. Price T Rowe Associates Inc. MD purchased a new position in shares of BioAtla in the 1st quarter worth about $45,000. Virtu Financial LLC bought a new stake in BioAtla in the first quarter worth about $103,000. Finally, Rinkey Investments bought a new stake in shares of BioAtla in the 2nd quarter worth approximately $35,000. Hedge funds and other institutional investors own 77.23% of the company’s stock.

Analyst Ratings Changes

BCAB has been the subject of several recent research reports. JMP Securities reiterated a “market outperform” rating and issued a $5.00 target price on shares of BioAtla in a research note on Monday, September 16th. HC Wainwright downgraded BioAtla from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 13th.

BioAtla Stock Performance

BioAtla stock opened at $1.51 on Tuesday. BioAtla, Inc. has a fifty-two week low of $1.14 and a fifty-two week high of $4.02. The stock has a market cap of $73.01 million, a P/E ratio of -0.89 and a beta of 1.03. The firm’s fifty day moving average price is $1.91 and its 200-day moving average price is $1.85.

BioAtla (NASDAQ:BCAB) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.12. The business had revenue of $11.00 million for the quarter. During the same period in the previous year, the business posted ($0.70) EPS. Sell-side analysts predict that BioAtla, Inc. will post -1.49 earnings per share for the current year.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.